mir-17 microRNA precursor family

From Wikipedia, the free encyclopedia
Jump to: navigation, search
mir-17 microRNA precursor family
Symbol mir-17
Rfam RF00051
miRBase MI0000071
miRBase family MIPF0000001
Other data
RNA type Gene; miRNA
Domain(s) Eukaryota
GO 0035195 0035068
SO 0001244

The miR-17 microRNA precursor family are a group of related small non-coding RNA genes called microRNAs that regulate gene expression. The microRNA precursor miR-17 family, includes miR-20a/b, miR-93, and miR-106a/b. With the exception of miR-93, these microRNAs are produced from several microRNA gene clusters, which apparently arose from a series of ancient evolutionary genetic duplication events, and also include members of the miR-19, and miR-25 families.[1] These clusters are transcribed as long non-coding RNA transcripts that are processed to form ~70 nucleotide microRNA precursors, that are subsequently processed by the Dicer enzyme to give a ~22 nucleotide products. The mature microRNA products are thought to regulate expression levels of other genes through complementarity to the 3' UTR of specific target messenger RNA.[2][3]

The paralogous miRNA gene clusters that give rise to miR-17 family microRNAs (miR-17~92, miR-106a~363, and miR-106b~25) have been implicated in a wide variety of malignancies and are sometimes referred to as oncomirs.[4] The oncogenic potential of these non-protein encoding genes was first identified in mouse viral tumorigenesis screens.[5][6][7] In humans, the activating mutations of miR-17~92 have been identified in non-Hodgkin's lymphoma, whereas the miRNA constituents of the clusters are overexpressed in a multiple cancer types.[8][9][10] High level expression of miR-17 family members induces cell proliferation, whereas deletion of the miR-17~92 cluster, in mice, is lethal and causes lung and lymphoid cell developmental defects.[11] In addition, in the nasopharyngeal carcinoma cell line, miR-20a and miR-20b has been shown to target the 3’ UTR of vascular endothelial growth factor (VEGF) and repress the expression of VEGF, which is an important angiogenic factor.[12][13]


  1. ^ Tanzer A, Stadler PF (2004). "Molecular evolution of a microRNA cluster.". J Mol Biol. 339: 327–35. doi:10.1016/j.jmb.2004.03.065. PMID 15136036. 
  2. ^ Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001). "Identification of novel genes coding for small expressed RNAs.". Science. 294 (5543): 853–8. doi:10.1126/science.1064921. PMID 11679670. 
  3. ^ Ambros V (2001). "microRNAs: tiny regulators with great potential.". Cell. 107 (7): 823–6. doi:10.1016/S0092-8674(01)00616-X. PMID 11779458. 
  4. ^ Hammond, SM. (Nov 2006). "RNAi, microRNAs, and human disease.". Cancer Chemother Pharmacol. 58 Suppl 1: s63–8. doi:10.1007/s00280-006-0318-2. PMID 17093929. 
  5. ^ Hwang HC, Martins CP, Bronkhorst Y, Randel E, Berns A, Fero ML, Clurman BE (2002). "Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis.". Proc Natl Acad Sci U S A. 99 (17): 11293–8. doi:10.1073/pnas.162356099. PMID 12151601. 
  6. ^ Wang CL, Wang BB, Bartha G, Li L, Channa N, Klinger M, Killeen N, Wabl M (2006). "Activation of an oncogenic microRNA cistron by provirus integration.". Proc Natl Acad Sci U S A. 103 (49): 18680–4. doi:10.1073/pnas.0609030103. PMID 17121985. 
  7. ^ Landais S, Landry S, Legault P, Rassart E (2007). "Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia.". Cancer Res. 67 (12): 5699–707. doi:10.1158/0008-5472.CAN-06-4478. PMID 17575136. 
  8. ^ Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M (2004). "Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma.". Cancer Res. 64 (9): 3087–95. doi:10.1158/0008-5472.CAN-03-3773. PMID 15126345. 
  9. ^ Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano CV, Tibiletti MG, Bertoni F (2007). "Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma.". Leuk Lymphoma. 48 (2): 410–2. doi:10.1080/10428190601059738. PMID 17325905. 
  10. ^ Mendell JT (2008). "miRiad roles for the miR-17-92 cluster in development and disease.". Cell. 133 (2): 217–22. doi:10.1016/j.cell.2008.04.001. PMC 2732113Freely accessible. PMID 18423194. 
  11. ^ Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, et al. (2008). "Targeted deletion reveals essential and overlapping functions of the miR-17~92 family of miRNA clusters.". Cell. 132 (5): 875–86. doi:10.1016/j.cell.2008.02.019. PMC 2323338Freely accessible. PMID 18329372. 
  12. ^ Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB, Zhang Y (Dec 27, 2006). "MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia". PLOS ONE. 1 (1): e116. doi:10.1371/journal.pone.0000116. PMC 1762435Freely accessible. PMID 17205120. 
  13. ^ Ye W, Lv Q, Wong CK, Hu S, Fu C, Hua Z, Cai G, Li G, Yang BB, Zhang Y (Mar 5, 2008). "The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation". PLOS ONE. 3 (3): e1719. doi:10.1371/journal.pone.0001719. PMC 2248708Freely accessible. PMID 18320040. 

Further reading[edit]

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65]

External links[edit]

  1. ^ Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-Tikhonenko A (2010). "The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors.". Cancer Res. 70 (20): 8233–46. doi:10.1158/0008-5472.CAN-10-2412. PMID 20940405. 
  2. ^ Xiang J, Wu J (2010). "Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis.". Curr Genomics. 11 (2): 129–35. doi:10.2174/138920210790886853. PMC 2874222Freely accessible. PMID 20885820. 
  3. ^ Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J, Xu N (2010). "Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level.". Int J Oncol. 37 (5): 1315–21. doi:10.3892/ijo_00000783. PMID 20878079. 
  4. ^ Hong L, Lai M, Chen M, Xie C, Liao R, Kang YJ, Xiao C, Hu WY, Han J, Sun P (2010). "The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence.". Cancer Res. 70 (21): 8547–57. doi:10.1158/0008-5472.CAN-10-1938. PMC 2970743Freely accessible. PMID 20851997. 
  5. ^ Osada H, Takahashi T (2010). "Review Article: let-7 and miR-17-92: Small-sized major players in lung cancer development.". Cancer Sci. 102 (1): 9–17. doi:10.1111/j.1349-7006.2010.01707.x. PMID 20735434. 
  6. ^ Cox MB, Cairns MJ, Gandhi KS, Carroll AP, Moscovis S, Stewart GJ, Broadley S, Scott RJ, Booth DR, Lechner-Scott J, ANZgene Multiple Sclerosis Genetics Consortium (2010). Jacobson S, ed. "MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood.". PLoS ONE. 5 (8): e12132. doi:10.1371/journal.pone.0012132. PMC 2920328Freely accessible. PMID 20711463. 
  7. ^ Yu J, Ohuchida K, Mizumoto K, Fujita H, Nakata K, Tanaka M (2010). "MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis and involved in cancer cell proliferation and invasion.". Cancer Biol Ther. 10 (8): 748. doi:10.4161/cbt.10.8.13083. PMID 20703102. 
  8. ^ Zhuo de X, Niu XH, Chen YC, Xin DQ, Guo YL, Mao ZB (2010). "Vitamin D3 up-regulated protein 1(VDUP1) is regulated by FOXO3A and miR-17-5p at the transcriptional and post-transcriptional levels, respectively, in senescent fibroblasts.". J Biol Chem. 285 (41): 31491–501. doi:10.1074/jbc.M109.068387. PMC 2951223Freely accessible. PMID 20656682. 
  9. ^ Kuhnert F, Kuo CJ (2010). "miR-17-92 angiogenesis micromanagement.". Blood. 115 (23): 4631–3. doi:10.1182/blood-2010-03-276428. PMID 20538815. 
  10. ^ Li H, Bian C, Liao L, Li J, Zhao RC (2010). "miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1.". Breast Cancer Res Treat. 126 (3): 565–575. doi:10.1007/s10549-010-0954-4. PMID 20505989. 
  11. ^ Budde H, Schmitt S, Fitzner D, Opitz L, Salinas-Riester G, Simons M (2010). "Control of oligodendroglial cell number by the miR-17-92 cluster". Development. 137 (13): 2127–32. doi:10.1242/dev.050633. PMID 20504959. 
  12. ^ Grillari J, Hackl M, Grillari-Voglauer R (2010). "miR-17-92 cluster: ups and downs in cancer and aging". Biogerontology. 11 (4): 501–6. doi:10.1007/s10522-010-9272-9. PMC 2899009Freely accessible. PMID 20437201. 
  13. ^ Wong P, Iwasaki M, Somervaille TC, Ficara F, Carico C, Arnold C, Chen CZ, Cleary ML (2010). "The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression". Cancer Res. 70 (9): 3833–42. doi:10.1158/0008-5472.CAN-09-3268. PMC 2862107Freely accessible. PMID 20406979. 
  14. ^ Ernst A, Campos B, Meier J, Devens F, Liesenberg F, Wolter M, Reifenberger G, Herold-Mende C, Lichter P, Radlwimmer B (2010). "De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures". Oncogene. 29 (23): 3411–22. doi:10.1038/onc.2010.83. PMID 20305691. 
  15. ^ He S, Yang S, Deng G, Liu M, Zhu H, Zhang W, Yan S, Quan L, Bai J, Xu N (2010). "Aurora kinase A induces miR-17-92 cluster through regulation of E2F1 transcription factor". Cell Mol Life Sci. 67 (12): 2069–76. doi:10.1007/s00018-010-0340-8. PMID 20300951. 
  16. ^ Olive V, Jiang I, He L (2010). "mir-17-92, a cluster of miRNAs in the midst of the cancer network". Int J Biochem Cell Biol. 42 (8): 1348–54. doi:10.1016/j.biocel.2010.03.004. PMID 20227518. 
  17. ^ Tran U, Zakin L, Schweickert A, Agrawal R, Döger R, Blum M, De Robertis EM, Wessely O (2010). "The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity". Development. 137 (7): 1107–16. doi:10.1242/dev.046045. PMC 2835326Freely accessible. PMID 20215348. 
  18. ^ Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y, Sun S (2010). "miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway". Hepatology. 51 (5): 1614–23. doi:10.1002/hep.23566. PMID 20209605. 
  19. ^ Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, Martinson J, Lotze MT, Marincola FM, Wang E, Fujita M, Okada H (2010). "miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy". J Transl Med. 8 (1): 17. doi:10.1186/1479-5876-8-17. PMC 2836279Freely accessible. PMID 20167088. 
  20. ^ Lindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L (2010). "Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients". Eur J Immunol. 40 (3): 888–98. doi:10.1002/eji.200940032. PMID 20148420. 
  21. ^ Mi S, Li Z, Chen P, He C, Cao D, Elkahloun A, Lu J, Pelloso LA, Wunderlich M, Huang H, Luo RT, Sun M, He M, Neilly MB, Zeleznik-Le NJ, Thirman MJ, Mulloy JC, Liu PP, Rowley JD, Chen J (2010). "Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia". Proc Natl Acad Sci U S A. 107 (8): 3710–5. doi:10.1073/pnas.0914900107. PMC 2840429Freely accessible. PMID 20133587. 
  22. ^ Hackl M, Brunner S, Fortschegger K, Schreiner C, Micutkova L, Mück C, Laschober GT, Lepperdinger G, Sampson N, Berger P, Herndler-Brandstetter D, Wieser M, Kühnel H, Strasser A, Rinnerthaler M, Breitenbach M, Mildner M, Eckhart L, Tschachler E, Trost A, Bauer JW, Papak C, Trajanoski Z, Scheideler M, Grillari-Voglauer R, Grubeck-Loebenstein B, Jansen-Dürr P, Grillari J (2010). "miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human aging". Aging Cell. 9 (2): 291–6. doi:10.1111/j.1474-9726.2010.00549.x. PMC 2848978Freely accessible. PMID 20089119. 
  23. ^ van Haaften G, Agami R (2010). "Tumorigenicity of the miR-17-92 cluster distilled". Genes Dev. 24 (1): 1–4. doi:10.1101/gad.1887110. PMC 2802185Freely accessible. PMID 20047995. 
  24. ^ Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, Pace KT, Yousef GM (2010). "The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma". J Urol. 183 (2): 743–51. doi:10.1016/j.juro.2009.09.086. PMID 20022054. 
  25. ^ Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L (2009). "miR-19 is a key oncogenic component of mir-17-92". Genes Dev. 23 (24): 2839–49. doi:10.1101/gad.1861409. PMC 2800084Freely accessible. PMID 20008935. 
  26. ^ Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A (2009). "Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas". Genes Dev. 23 (24): 2806–11. doi:10.1101/gad.1872909. PMC 2800095Freely accessible. PMID 20008931. 
  27. ^ Guo L, Sun B, Sang F, Wang W, Lu Z (2009). Poon AF, ed. "Haplotype distribution and evolutionary pattern of miR-17 and miR-124 families based on population analysis". PLoS ONE. 4 (11): e7944. doi:10.1371/journal.pone.0007944. PMC 2775919Freely accessible. PMID 19956752. 
  28. ^ ZHANG ZW, AN Y, TENG CB (2009). "[The roles of miR-17-92 cluster in mammal development and tumorigenesis]". Yi Chuan. 31 (11): 1094–100. PMID 19933089. 
  29. ^ Sun H, Li QW, Lv XY, Ai JZ, Yang QT, Duan JJ, Bian GH, Xiao Y, Wang YD, Zhang Z, Liu YH, Tan RZ, Yang Y, Wei YQ, Zhou Q (2010). "MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation". Mol Biol Rep. 37 (6): 2951–8. doi:10.1007/s11033-009-9861-3. PMID 19821056. 
  30. ^ Yan HL, Xue G, Mei Q, Wang YZ, Ding FX, Liu MF, Lu MH, Tang Y, Yu HY, Sun SH (2009). "Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis". EMBO J. 28 (18): 2719–32. doi:10.1038/emboj.2009.214. PMC 2750010Freely accessible. PMID 19696742. 
  31. ^ Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B, Meijer GA (2009). "MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression". Br J Cancer. 101 (4): 707–14. doi:10.1038/sj.bjc.6605037. PMC 2736819Freely accessible. PMID 19672269. 
  32. ^ Beveridge NJ, Tooney PA, Carroll AP, Tran N, Cairns MJ (2009). "Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation". Cell Signal. 21 (12): 1837–45. doi:10.1016/j.cellsig.2009.07.019. PMID 19666108. 
  33. ^ Shan SW, Lee DY, Deng Z, Shatseva T, Jeyapalan Z, Du WW, Zhang Y, Xuan JW, Yee SP, Siragam V, Yang BB (2009). "MicroRNA MiR-17 retards tissue growth and represses fibronectin expression". Nat Cell Biol. 11 (8): 1031–8. doi:10.1038/ncb1917. PMID 19633662. 
  34. ^ Ebi H, Sato T, Sugito N, Hosono Y, Yatabe Y, Matsuyama Y, Yamaguchi T, Osada H, Suzuki M, Takahashi T (2009). "Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers". Oncogene. 28 (38): 3371–9. doi:10.1038/onc.2009.201. PMID 19597473. 
  35. ^ Carraro G, El-Hashash A, Guidolin D, Tiozzo C, Turcatel G, Young BM, De Langhe SP, Bellusci S, Shi W, Parnigotto PP, Warburton D (2009). "miR-17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-Cadherin distribution". Dev Biol. 333 (2): 238–50. doi:10.1016/j.ydbio.2009.06.020. PMC 2735610Freely accessible. PMID 19559694. 
  36. ^ Northcott PA, Fernandez-L A, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM, Kenney AM, Taylor MD (2009). "The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors". Cancer Res. 69 (8): 3249–55. doi:10.1158/0008-5472.CAN-08-4710. PMC 2836891Freely accessible. PMID 19351822. 
  37. ^ Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, Rosati S, Schuuring E, Kluin P, van den Berg A (2009). "Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma". Mod Pathol. 22 (4): 547–55. doi:10.1038/modpathol.2009.10. PMID 19287466. 
  38. ^ Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A, He L, Ellison D, Gilbertson RJ, Hannon G, Roussel MF (2009). "The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma". Proc Natl Acad Sci U S A. 106 (8): 2812–7. doi:10.1073/pnas.0809579106. PMC 2636735Freely accessible. PMID 19196975. 
  39. ^ Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, Stano Kozubik K, Smardova J, Brychtova Y, Doubek M, Trbusek M, Mayer J, Pospisilova S (2009). "miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities". Leukemia. 23 (6): 1159–63. doi:10.1038/leu.2008.377. PMID 19158830. 
  40. ^ Nagel S, Venturini L, Przybylski GK, Grabarczyk P, Schmidt CA, Meyer C, Drexler HG, Macleod RA, Scherr M (2009). "Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia". Leuk Lymphoma. 50 (1): 101–8. doi:10.1080/10428190802626632. PMID 19148830. 
  41. ^ Foshay KM, Gallicano GI (2009). "miR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation". Dev Biol. 326 (2): 431–43. doi:10.1016/j.ydbio.2008.11.016. PMID 19073166. 
  42. ^ Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB (2008). "MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc". Proc Natl Acad Sci U S A. 105 (50): 19678–83. doi:10.1073/pnas.0811166106. PMC 2598727Freely accessible. PMID 19066217. 
  43. ^ Petrocca F, Vecchione A, Croce CM (2008). "Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling". Cancer Res. 68 (20): 8191–4. doi:10.1158/0008-5472.CAN-08-1768. PMID 18922889. 
  44. ^ Pickering MT, Stadler BM, Kowalik TF (2009). "miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression". Oncogene. 28 (1): 140–5. doi:10.1038/onc.2008.372. PMC 2768269Freely accessible. PMID 18836483. 
  45. ^ Cloonan N, Brown MK, Steptoe AL, Wani S, Chan WL, Forrest AR, Kolle G, Gabrielli B, Grimmond SM (2008). "The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition". Genome Biol. 9 (8): R127. doi:10.1186/gb-2008-9-8-r127. PMC 2575517Freely accessible. PMID 18700987. 
  46. ^ Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE (2008). "Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype". Am J Pathol. 173 (3): 856–64. doi:10.2353/ajpath.2008.080096. PMC 2527078Freely accessible. PMID 18688024. 
  47. ^ Xu X, Hong Y, Kong C, Xu L, Tan J, Liang Q, Huang B, Lu J (2008). "Protein tyrosine phosphatase receptor-type O (PTPRO) is co-regulated by E2F1 and miR-17-92". FEBS Lett. 582 (19): 2850–6. doi:10.1016/j.febslet.2008.07.017. PMID 18644370. 
  48. ^ Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, Goto H, Takahashi T (2008). "Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster". Cancer Res. 68 (14): 5540–5. doi:10.1158/0008-5472.CAN-07-6460. PMID 18632605. 
  49. ^ Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru A, Yamashita S (2008). "Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells". Cancer Sci. 99 (6): 1147–54. doi:10.1111/j.1349-7006.2008.00800.x. PMID 18429962. 
  50. ^ Mendell JT (2008). "miRiad roles for the miR-17-92 cluster in development and disease". Cell. 133 (2): 217–22. doi:10.1016/j.cell.2008.04.001. PMC 2732113Freely accessible. PMID 18423194. 
  51. ^ Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T (2008). "Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters". Cell. 132 (5): 875–86. doi:10.1016/j.cell.2008.02.019. PMC 2323338Freely accessible. PMID 18329372. 
  52. ^ Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K (2008). "Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes". Nat Immunol. 9 (4): 405–14. doi:10.1038/ni1575. PMC 2533767Freely accessible. PMID 18327259. 
  53. ^ Wang Q, Li YC, Wang J, Kong J, Qi Y, Quigg RJ, Li X (2008). "miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130". Proc Natl Acad Sci U S A. 105 (8): 2889–94. doi:10.1073/pnas.0800178105. PMC 2268555Freely accessible. PMID 18287052. 
  54. ^ Xu W, Li JY, Shen QD, Li L, Yu H (2007). "[DNA sequencing of miR-17-92 cluster at chromosome 13q31-q32 in mantel cell lymphoma cell lines]". Zhongguo Shi Yan Xue Ye Xue Za Zhi. 15 (5): 986–8. PMID 17956675. 
  55. ^ Boggs RM, Moody JA, Long CR, Tsai KL, Murphy KE (2007). "Identification, amplification and characterization of miR-17-92 from canine tissue". Gene. 404 (1–2): 25–30. doi:10.1016/j.gene.2007.08.015. PMID 17904311. 
  56. ^ Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL (2007). "Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells". Dev Biol. 310 (2): 442–53. doi:10.1016/j.ydbio.2007.08.007. PMC 2052923Freely accessible. PMID 17765889. 
  57. ^ Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M (2007). "Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development". Cancer Sci. 98 (9): 1482–90. doi:10.1111/j.1349-7006.2007.00531.x. PMID 17608773. 
  58. ^ Matsubara H, Takeuchi T, Nishikawa E, Yanagisawa K, Hayashita Y, Ebi H, Yamada H, Suzuki M, Nagino M, Nimura Y, Osada H, Takahashi T (2007). "Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92". Oncogene. 26 (41): 6099–105. doi:10.1038/sj.onc.1210425. PMID 17384677. 
  59. ^ Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano CV, Tibiletti MG, Bertoni F (2007). "Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma". Leuk Lymphoma. 48 (2): 410–2. doi:10.1080/10428190601059738. PMID 17325905. 
  60. ^ Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M (2007). "Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells". Blood. 109 (10): 4399–405. doi:10.1182/blood-2006-09-045104. PMID 17284533. 
  61. ^ Novotny GW, Sonne SB, Nielsen JE, Jonstrup SP, Hansen MA, Skakkebaek NE, Rajpert-De Meyts E, Kjems J, Leffers H (2007). "Translational repression of E2F1 mRNA in carcinoma in situ and normal testis correlates with expression of the miR-17-92 cluster". Cell Death Differ. 14 (4): 879–82. doi:10.1038/sj.cdd.4402090. PMID 17218954. 
  62. ^ Hossain A, Kuo MT, Saunders GF (2006). "Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA". Mol Cell Biol. 26 (21): 8191–201. doi:10.1128/MCB.00242-06. PMC 1636750Freely accessible. PMID 16940181. 
  63. ^ Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T (2005). "A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation". Cancer Res. 65 (21): 9628–32. doi:10.1158/0008-5472.CAN-05-2352. PMID 16266980. 
  64. ^ Sawera M, Gorodkin J, Cirera S, Fredholm M (2005). "Mapping and expression studies of the mir17-92 cluster on pig chromosome 11". Mamm Genome. 16 (8): 594–8. doi:10.1007/s00335-005-0013-3. PMID 16180141. 
  65. ^ Shen J, Ambrosone CB, Zhao H (2009). "Novel genetic variants in microRNA genes and familial breast cancer". Int J Cancer. 124 (5): 1178–82. doi:10.1002/ijc.24008. PMID 19048628.